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Background: The decline in efficacy of artesunate (AS) and mefloquine (MQ) is now the major concern in areas
along the Thai-Cambodian and Thai-Myanmar borders.
Methods: The correlation between polymorphisms of pfatp6, pfcrt, pfmdr1 and pfmrp1 genes and in vitro sensitivity of
Plasmodium falciparum isolates to the artemisinin-based combination therapy (ACT) components AS and MQ, including
the previously used first-line anti-malarial drugs chloroquine (CQ) and quinine (QN) were investigated in a total of 119
P. falciparum isolates collected from patients with uncomplicated P. falciparum infection during 2006–2009.
Results: Reduced in vitro parasite sensitivity to AS [median (95% CI) IC50 3.4 (3.1-3.7) nM] was found in 42% of the isolates,
whereas resistance to MQ [median (95% CI) IC50 54.1 (46.8-61.4) nM] accounted for 58% of the isolates. Amplification
of pfmdr1 gene was strongly associated with a decline in susceptibility of P. falciparum isolates to AS, MQ and QN.
Significant difference in IC50 values of AS, MQ and QN was observed among isolates carrying one, two, three, and ≥ four
gene copies [median (95% CI) AS IC50: 1.6 (1.3-1.9), 1.8 (1.1-2.5), 2.9 (2.1-3.7) and 3.1 (2.5-3.7) nM, respectively; MQ IC50: 19.2
(15.8-22.6), 37.8 (10.7-64.8), 55.3 (47.7-62.9) and 63.6 (49.2-78.0) nM, respectively; and QN IC50: 183.0 (139.9-226.4), 256.4
(83.7-249.1), 329.5 (206.6-425.5) and 420.0 (475.2-475.6) nM, respectively]. The prevalence of isolates which were resistant to
QN was reduced from 21.4% during the period 2006–2007 to 6.3% during the period 2008–2009. Pfmdr1 86Y was found to
be associated with increased susceptibility of the parasite to MQ and QN. Pfmdr1 1034C was associated with decreased
susceptibility to QN. Pfmrp1 191Y and 1390I were associated with increased susceptibility to CQ and QN, respectively.
Conclusion: High prevalence of CQ and MQ-resistant P. falciparum isolates was observed during the four-year observation
period (2006–2009). AS sensitivity was declined, while QN sensitivity was improved. Pfmdr1 and pfmrp1 appear to be the
key genes that modulate multidrug resistance in P. falciparum.
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Southeast Asia, particularly the Thai-Cambodian border,
is one of the malaria-endemic region where multidrug-
resistant Plasmodium falciparum malaria has been
reported [1]. In the 1960s and 1970s, chloroquine (CQ) re-
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article, unless otherwise stated.in the 1980s, resistance to sulphadoxine and pyrimeth-
amine was reported [2]. In 1984, mefloquine (MQ) was
firstly introduced for clinical use as first-line treat-
ment for uncomplicated multidrug-resistant P. falciparum
malaria in Thailand, but MQ resistance was rapidly devel-
oped four years after its implementation. Following the
decline in clinical efficacy of MQ, the artemisinin-
based combination therapy (ACT) using the artesunate-
mefloquine combination was introduced as first-line reat-
ment in 1994 [3]. Cure rate was improved to over 90% andntral Ltd. This is an Open Access article distributed under the terms of the
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reduced [4,5]. Artemisinin resistance however, initially
occurred during 2006–2007 in areas along the Thai-
Cambodian border [6]. With regard to the Thai-Myanmar
border, treatment failure following ACT has been increas-
ing especially in Tak province [7]. Studies during 2008–
2009 showed a marked decline in the 42-day cure rate from
99.2 to 72.58% [8,9]. It is unclear whether artemisinin re-
sistance has spread from the eastern to the western border
of the country. Monitoring and identifying factors contrib-
uting to this low cure rate is necessary for the country’s fu-
ture perspective of malaria control policy. Applying genetic
analysis as a tool for detecting the genetic change of malaria
parasite genes that have been shown to link with the de-
cline in efficacy of artesunate (AS) and MQ; i.e., pfmdr1
[10], pfatp6 [11] and pfmrp1 [12-14], in association with
the in vitro sensitivity of the parasite to both combination
partners, would help to detect early changes in P. falcip-
arum sensitivity to this combination therapy.
In the present study, the association between the poly-
morphisms of pfatp6, pfcrt, pfmdr1, and pfmrp1 genes
and in vitro sensitivity of P. falciparum isolates to AS,
MQ, as well as CQ and quinine (QN) was investigated
in P. falciparum isolates collected from the Thai-
Myanmar border. In addition, the change in parasite
genetic patterns and in vitro sensitivity over the period
2006–2009 was also examined.Methods
Blood samples
A total of 130 P. falciparum isolates were collected from
patients with uncomplicated P. falciparum infection
prior to treatment with a three-day combination regi-
men (25 mg/kg body weight MQ and 12 mg/kg body
weight AS) for investigation of the polymorphisms of
candidate molecular markers of anti-malarial drug resist-
ance and in vitro parasite sensitivity. The study was con-
ducted at Mae Tao clinic, Mae Sot District, Tak
Province, Thailand during 2006–2009. Fifty-seven and
73 isolates were collected from patients during 2006–
2007 and 2008–2009, respectively (Figure 1). The study
protocol was approved by the Ethics Committee of the
Ministry of Public Health of Thailand and written in-
formed consents for study participations were obtained
from all patients before study.Culture system and in vitro sensitivity assay
All parasite isolates were adapted to continuous culture
according to the method of [15] with modification. The
laboratory-adapted 3D7 (CQ-sensitive) and K1 (CQ-re-
sistant) P. falciparum were used as control parasite
clones. Susceptibility of P. falciparum isolates to AS,
MQ, CQ and QN was investigated using SYBR Green Iassay [16,17]. Highly synchronous ring stage parasites were
used in each assay. An aliquot of parasite inoculum (50 μl)
with 2% parasitaemia and 1% haematocrit was added into
each well of the 96-well microtitre plate. The plate was pre-
dosed with each anti-malarial drug at eight final concentra-
tions as follows: AS: 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25,
and 50 nM; MQ: 3.13, 6.25, 12.5, 25, 50, 100, 200, and 400
nM; CQ (3.13, 7.81, 15.63, 31.25, 62.5, 125, 250, and 500
nM); and QN: 7.81, 15.63, 31.25, 62.5, 125, 250, 500, and
1,000 nM. Standard compounds of all anti-malarial drugs
were purchased from Sigma-Aldrich Co (St Louis, MO,
USA). All were stored at −20°C as 10 mM stock solutions
in 50% ethanol. The experiments were repeated three
times, triplicate for each experiment. IC50 value (concentra-
tion that inhibits parasite growth by 50%) was used as an
indicator for anti-malarial susceptibility and was deter-
mined from a log-dose response analysis using the Calcu-
Syn™ computer program (Biosoft, Cambridge, UK). The
criterion used for susceptibility of the parasite isolates to
CQ was as follow: sensitive (S: IC50 <25 nM), moderately
resistant (MR: 25 ≤ IC50 <100 nM), and highly resistant
(HR: IC50 ≥100 nM). QN susceptibility was categorized
into two levels, i.e., S (IC50 <500 nM), and resistant (R:
IC50 ≥500 nM). MQ susceptibility was categorized into
two levels, i.e., “sensitive” (IC50 ≤24 nM) and “resistant”
(IC50 >24 nM). For AS, the susceptibility was classified as
“sensitive” (IC50 ≤ upper limit of 95% CI of the median
IC50) and “declined sensitivity” (IC50 > upper limit of 95%
confidence interval (CI) of the median IC50) [18].Investigation of polymorphisms of pfcrt, pfmdr1, pfatp6,
and pfmrp1 using PCR-RFLP
Genomic DNA was extracted from all samples (culture-
adapted P. falciparum; Figure 1) using chelex resin
modified technique [19]. Prior to being used as a DNA
template, concentration of the malaria genomic DNA
was determined by spectrophotometry (NanodropTM,
Thermo fisher Scientific, Massachusetts, USA).
Previously published nested and PCR-RFLP methods
were employed to detect the polymorphisms of pfcrt
gene at amino acid residues 76, 220, 271, 326, 356, and
371 [20]; pfmdr1 gene at amino acid residues 86, 184,
1034, 1042, and 1246 [21,22]; pfatp6 gene at amino acid
residues 37, 693, 769, 898 [23]; pfmrp1 gene at amino
acid residues 191 and 437 [24]; and pfmrp1 gene at
amino acid residues 876, 1390 and 1466 [25].Detection of pfatp6 and pfmdr1 gene copy number by
SYBR Green I real-time PCR
Pfatp6 and pfmdr1 gene copy number in all samples
(Figure 1) was determined by SYBR Green I real-time
PCR (iCycler™, Bio-Rad, California, USA) using the de-
fault thermocycler program: 10min of pre-incubation at
Figure 1 Frameworks of in vitro sensitivity and molecular analysis in Plasmodium falciparum isolates collected during 2006–2009. The
number in parentheses signify the number of isolates included in the analysis.
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at 60°C. The oligonucleotide primers used were those
previously designed by Ferreira et al. [26] with modifica-
tion. Individual real-time PCR reaction was carried out
in a 25 μl reaction volume in a 96-well plate containing
2 μl of DNA (50 ng), 1 μM each of sense and antisense
primer and 12.5 μl of Platinum™ PCR SuperMix (Invitro-
gen, California, USA).
The 2-ΔΔCt method of relative quantification was
adapted to estimate copy number in P. falciparum genes.
The genomic DNA extracted from P. falciparum 3D7
clone known to harbour a single copy of each gene was
used as a calibrator, while Pf-β-actin 1 served as the
house-keeping gene in all experiments. Dd2 genomic
DNA carrying four copies of pfmdr1 was used as a sec-
ond calibrator. The threshold cycle (Ct) was determined
as the increase in reporter signal, which was first de-
tected above baseline. Results were analysed by a com-
parative Ct method based on the assumption that the
target (pfatp6 and pfmdr1) and reference (pf-β-actin 1)
genes were amplified with the same efficiency within an
appropriate range of DNA concentrations.The ΔΔCt calculation for the relative quantification of
target was as follow: ΔΔCt = (Ct, target gene −Ct, Pf-β-
actin1)x − (Ct, target gene −Ct, Pf-β-actin1)y, where x repre-
sents unknown sample and y represents P. falciparum 3D7
clone. Results for each sample was expressed as an N-fold
change in χ target gene copies, normalized to Pf-β-actin-1
relative to the copy number of the target gene in P. falcip-
arum 3D7 clone, according to the following equation:
amount of target = 2-ΔΔCt. A minimum of two experiments
were carried out for each gene and each sample. In each ex-
periment, each individual sample was analysed in duplicate
wells and the Ct of each well was recorded at the end of the
reaction.
Statistical analysis
The association between in vitro sensitivity of P. falcip-
arum isolates and polymorphisms of pfcrt, pfmdr1,
pfmrp1, and pfatp6 was analysed using Chi-square and
Mann–Whitney U tests. Correlation between the two
quantitative variables was evaluated using Spearman cor-
relation test. The qualitative variables are summarized as
proportions and percentages and the quantitative variables
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nificance level was set at α = 0.05 for all tests (SPSS version
15; SPSS, Chicago, Illinois, USA).
Results
In vitro sensitivity of Plasmodium falciparum isolates
In vitro sensitivity to AS, MQ, CQ, and QN was success-
fully evaluated in a total of 119 P. falciparum isolates
(Figure 1 and Table 1), 56 and 63 isolates collected dur-
ing 2006–2007 and 2008–2009, respectively (Figure 1
and Table 2). Isolates with declined sensitivity to AS
[median (95% CI) 3.4 (3.1-3.7) nM] were observed in 42%
(50 isolates). Fifty-eight per cent (69 isolates) were identi-
fied as MQ-resistant [median (95% CI) = 54.1 (46.8-61.4)
nM]. Almost all (99.2%, 118 isolates) were identified as
moderately and highly CQ-resistant; only one (0.8%) iso-
late was identified as CQ-sensitive (IC50 values = 9.6 nM).
About 13% (16 isolates) were identified as QN-resistant
[median (95% CI) = 648.9 (621.2-676.5) nM]. A positive
significant correlation was observed between the IC50
values of MQ and AS (r = +0.662; p <0.001), MQ and QN
(r = +0.750; p <0.001), and AS and QN (r = +0.625;
p <0.001) (Figure 2). There was no significant difference in
the IC50 values of all drugs between isolates collected
during the two periods. However, the prevalence of QN-
resistant isolates collected during 2008–2009 was signifi-
cantly lower than during 2006–2007 (p = 0.016).
Candidate molecular markers of antimalarial drug
resistance in Plasmodium falciparum isolates
Pfatp6 mutation
No mutation in pfatp6 at the target amino acid residues 37,
639 and 769 was found in any isolate (0/87, 0/130, andTable 1 In vitro sensitivity of Plasmodium falciparum
isolates (represented by IC50 values) to chloroquine (CQ),
quinine (QN), mefloquine (MQ), and artesunate (AS) and
their sensitivity classification
Drug Sensitivity classification % (n) IC50, nM
AS All 100 (119) 2.0 (1.7–2.3)
Sensitive (IC50 ≤2.3 nM) 58.0 (69) 1.4 (1.8–2.8)
Declined sensitivity (IC50 >2.3 nM) 42.0 (50) 3.4 (3.1–3.7)
MQ All 100 (119) 30.1 (21.8–33.3)
Sensitive 42.0 (50) 15.2 (12.8–17.6)
Resistant 58.0 (69) 54.1 (46.8–61.4)
CQ All 100 (119) 72.3 (67.3–77.3)
Sensitive 0.8 (1) 9.6
Moderate resistant 73.1 (87) 66.6 (63.5–69.7)
Highly resistant 26.1 (31) 131.6 (118.9–144.4)
QN All 100 (119) 231.7 (192.2–271.2)
Sensitive 86.6 (103) 222.6 (195.5–249.8)
Resistant 13.4 (16) 648.9 (621.2–676.5)
Data presented as median (95% CI) and percentage (number).0/108 isolate, respectively), whereas the mutation at 898
was detected in six out of 121 (5.0%) isolates. Almost all
isolates collected during 2006–2007 (100%) and 2008–2009
(93.7%) carried wild type pfatp6 at the target amino acid
residues 37, 639, 769, and 898. There was a significant dif-
ference in the prevalence of isolates collected during 2006–
2007 (0%, 0/57) and 2008–2009 (9.4%, 6/64) with regard to
the mutation at the amino acid residue 898 (p = 0.018).
Pfcrt mutation
Almost all isolates carried mutated pfcrt gene. The
prevalence of gene mutation at codons 76T, 220S, 271E,
326S, and 371I was 99.2% (128/129), while the mutation
at the codon 356T was 98.4% (127/129).
Pfmdr1 mutation
No mutation in pfmdr1 at the codons 1042D and 1246Y
was observed (0/130 and 0/130) in any isolate collected
during the two investigation periods. The prevalence of
pfmdr1 wild type at the target amino acid residue 86 was
significantly higher in isolates collected during 2008–2009
(100%, 73/73) compared with 2006–2007 (94.5%, 52/55)
(p = 0.043). The prevalence of pfmdr1 wild type at the tar-
get amino acid residue 184 in isolates collected during
2006–2007 and 2008–2009 was 100% (57/57) and 94.5%
(69/73), respectively. For the target amino acid residue
1034, mutant, heterozygous mutant and wild type isolates
were detected in 15.8% (14/57), 56.6% (34/57) and 24.6%
(9/57) of the isolates collected during 2006–2007, respect-
ively. The prevalence of the mutant and heterozygous mu-
tant at the same amino acid target was detected in 98.6 and
1.4% of the isolates collected during 2008–2009, respect-
ively. No wild type isolate was found at this target amino
acid. The prevalence of gene mutation at the amino acid
residue 1034 was significantly higher in isolates collected
between 2008–2009 compared with 2006–2007 (p < 0.001).
Pfmrp1 mutation
No mutation in pfmrp1 at the codon 1466R was observed
(0/130) in any isolate collected during both periods. The
mutations at amino acid residues 191, 437, 876, and 1390
were detected in 86.9% (113/130), 89.1% (115/129), 74.6%
(97/130) and 26.2% (34/130), respectively. The prevalence
of isolates with mutations at amino acid residues 191 and
437 collected during 2006–2007 vs 2008–2009 were 84.2%
(48/57) vs 89.0% (65/73) and 85.7% (48/56) vs 91.8% (68/
73), respectively. The prevalence of isolates with mutations
at amino acid residues 876 (p < 0.001) and 1390 (p =
0.037) was significantly higher in 2008–2009 (42.5%, 31/
73) compared with 2006–2007 (5.3%, 3/57).
Pfmdr1 copy number
Isolates which carried one, two, three, four, five, six and
eight gene copies were found in 48.8% (60/123), 15.4%
Table 2 In vitro sensitivity of Plasmodium falciparum isolates collected during 2006–2007 and 2008–2009 to
chloroquine (CQ), quinine (QN), mefloquine (MQ), and artesunate (AS) and their sensitivity classification
Drug Sensitivity
classification
Year 2006–2007 Year 2008–2009
% (n) IC50, nM % (n) IC50, nM
AS All 100 (56) 2.0 (1.5–2.4) 100 (63) 2.0 (1.5–2.5)
Sensitive 60.7 (34) 1.4 (1.3–1.6) 58.7 (37) 1.4 (1.1–1.8)
Declined sensitivity 39.3 (22) 3.1 (2.8–3.3) 41.3 (26) 3.7 (3.2–4.2)
MQ All 100 (56) 30.4 (18.0–42.7) 100 (63) 28.8 (16.7–41.0)
Sensitive 42.9 (24) 13.8 (11.3–16.3) 41.3 (26) 16.2 (13.2–19.2)
Resistant 57.1 (32) 51.5 (40.3–62.7) 58.3 (37) 58.7 (49.3–68.1)
CQ All 100 (56) 69.9 (62.8–77.1) 100 (63) 72.3 (65.4–79.2)
Sensitive 1.8 (1) 9.6 – –
Moderate resistant 76.8 (43) 65.9 (59.9–72.0) 69.8 (44) 66.6 (62.3–70.8)
Highly resistant 21.4 (12) 124.3 (108.1–140.6) 30.2 (19) 132.3 (68.1–196.5)
QN All 100 (56) 236.3 (186.2–286.4) 100 (63) 230.5 (164.8–296.2)
Sensitive 78.6 (44) 223.0 (178.6–267.3) 93.7 (59) 214.9 (150.4–279.4)
Resistant 21.4 (12) 648.9 (606.1–691.6) 6.3 (4)** 593.6 (491.0–696.2)
Data presented as median IC50 (95% CI) and percentage (number).
**Significant lower proportion than isolates collected from 2006–2007 (p = 0.016, Chi–square test).
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3.3% (4/123), and 0.8% (1/123), respectively. For the
period 2006–2007, the isolates which carried one, two,
three and four gene copies were found in 47.4% (27/57),
19.3% (11/57), 12.3% (7/57) and 21.1% (12/57), respect-
ively. About 50% (33/66), 12.1% (8/66), 15.2% (10/66),
13.6% (9/66), 1.5% (1/66), 6.1% (4/66), and 1.5% (1/66)
of the isolates collected during 2007–2008 carried one,Figure 2 The three-dimensional scatter diagram and the regression li
mefloquine (MQ), quinine (QN) and artesunate (AS).two, three, four, five, six and eight gene copies, respect-
ively. There was no significant difference in the preva-
lence of pfmdr1 gene copy in isolates collected during
the two periods.
Pfatp6 copy number
All of the 67 isolates under the analysis from the two pe-
riods carried only one gene copy.ne representing relationships between IC50 (nM) values of
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molecular markers of anti-malarial drug resistance and
in vitro sensitivity of Plasmodium falciparum isolates
The association between polymorphisms of candidate
molecular markers of anti-malarial drug resistance and
in vitro sensitivity to anti-malarial drugs was investigated
in 119 matched-paired P. falciparum isolates (Figure 3).Pfatp6 mutation and pfatp6 copy number
No significant association was observed between pfatp6
mutation including pfatp6 copy number and in vitro
sensitivity of P. falciparum isolates to all drugs.Pfcrt mutation
Significant association was observed between CQ resist-
ance and pfcrt mutations at codons 76T, 220S, 271E,
326S, and 371I. Only one CQ sensitive isolate (IC50 9.6
nM) carried wild type genotype at codons 76, 220, 271,


























































Figure 3 The relationship between median IC50 values of quinine (QN
pfmdr1 and pfmrp1 gene in Plasmodium falciparum isolates. Associatio
test), S1034C (p = 0.018, Kruskal-Wallis test) and pfmrp1 F1390I mutation (p
(p = 0.005, Mann–Whitney U test); and (C) CQ IC50 and pfmrp1 H191Y mutaPfmdr1 mutation
The IC50 values of MQ and QN were significantly lower
in the three (out of 117) isolates with 86Y mutation
compared with those carried wild type (86 N) genotype
[median (95% CI) MQ IC50: 30.4 (21.9-38.8) vs 8.1 (3.4-
9.1) nM, p = 0.005; median (95% CI) QN IC50: 236.3
(195.7-276.9) vs 86.4 (32.2-119.1) nM, p = 0.015). The
isolates carrying 1034S had significantly lower QN IC50
than that carrying 1034SC [IC50 (95%CI) 134.3 (46.3-
222.6) vs 230.5(168.3-292.7) nM, p = 0.007].Pfmrp1 mutation
CQ IC50 was significantly lower in isolates carrying 191Y
compared with that carrying wild type (H) genotype
[median (95% CI) IC50 81.4 (58.2-104.7) and 69.9 (65.0-
74.9) nM, respectively; p = 0.008]. The QN IC50 was sig-
nificantly lower in isolates carrying 1390I compared with
that carrying wild type 1390F genotype [median (95%









































), mefloquine (MQ) and chloroquine (CQ) and the mutations of
n between (A) QN IC50 and pfmdr1 N86Y (p = 0.015, Mann–Whitney U
= 0.039, Mann–Whitney U test); (B) MQ IC50 and pfmdr1 N86Y mutation
tion (p = 0.008, Mann–Whitney U test).
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A marked difference in IC50 values of AS, MQ and QN
was observed among isolates carrying one, two, three,
and ≥ four gene copies [median (95% CI) AS IC50: 1.6
(1.3-1.9), 1.8 (1.1-2.5), 2.9 (2.1-3.7) and 3.1 (2.5-3.7) nM,
p < 0.001; MQ IC50: 19.2 (15.8-22.6), 37.8 (10.7-64.8),
55.3 (47.7-62.9) and 63.6 (49.2-78.0) nM, p < 0.001; and
QN IC50: 183.0 (139.9-226.4), 256.4 (83.7-249.1), 329.5
(206.6-425.5) and 420.0 (475.2-475.6) nM, respectively,
p < 0.001]. Significant positive correlation was found be-
tween the increased pfmdr1 copy number and in vitro
sensitivity of P. falciparum isolates to AS (r = +0.47, p <
0.001), MQ (r = +0.65, p < 0.001), and QN (r = +0.50, p <
0.001), while a significant negative correlation was found
with CQ (r = −0.19, p = 0.038) (Figure 4).
Discussion
The present study investigated the relationship bet-
ween P. falciparum gene polymorphisms (pfatp6, pfcrt,
pfmdr1, and pfmrp1) and in vitro sensitivity of P. falcip-
arum isolates to the ACT combination partners AS andFigure 4 Correlation between pfmdr1 copy number and in vitro sensi
(B) quinine (QN), (C) mefloquine (MQ), and, (D) artesunate (AS).MQ, including CQ and QN in a multidrug-resistant area
along the Thai-Myanmar border during the two periods
(2006–2007 and 2008–2009). Results suggest a signifi-
cant change in the prevalence and pattern of pfatp6,
pfmdr1 and pfmrp1 gene polymorphisms with no change
in the in vitro sensitivity profiles of the parasite during
the two periods. Decline in sensitivity of P. falciparum
to MQ was continuously reported during 1991–1994
when MQ monotherapy was employed in Thailand [27].
However, until a decade after the switch of first-line
treatment to AS-MQ combination, high prevalence and
intensity of MQ resistance was reported (32%, 46% and
58% during 1998–2005 [28], 2007–2008 [29], and 2006–
2009 (the current study), respectively). While evidence
of artemisinin resistance was documented in Western
Cambodia during the period 2006–2007 [30,31], sensitiv-
ity of P. falciparum isolates in this area to AS during
the same period was generally considered satisfactory
[18,29,32,33]. Subsequent reports on a decline in AS
sensitivity [7,9] nevertheless, has created a major con-
cern on the future use of AS in combination therapy.tivity of Plasmodium falciparum isolates to (A) chloroquine (CQ),
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ance, the upper limit of 95% CI of median IC50 value of
AS in isolates collected from all patients (2.3 nM) was
used as a cut-off level of AS resistance in the present
study. Based on this cut-off level, approximately 42% of
the isolates were classified as declined sensitivity to AS.
The prevalence of isolates with MQ resistance and de-
clined sensitivity to AS observed in the present study
were similar to that previously reported (58 vs 57.6%
and 42 vs 36.7%, respectively) [34]. This cut-off criteria
for defining AS resistance (the upper limit of 95% CI of
median IC50 value of AS) was slightly lower in the
current study (2.3 nM) compared with the previous
study (2.8 nM) [34]. The sensitivity to AS (IC50: 2.0 vs
1.7 nM) and MQ (30.1 vs 34.0) were comparable with
that reported in the isolates collected from Cambodia
during the same period [35].
It was noted for the improvement of parasite sensitiv-
ity in this area to CQ and QN since the introduction of
AS-MQ combination in Thailand in 1995. There was
even one isolate that was sensitive to CQ. In 1991–1992
and 1994, the degree of CQ resistance in the country
was high [median (95% CI) IC50 193.2 (148.24-251.85)
and 157.0 (124.11-198.73) nM, respectively] [27], but
was improved during the 1997, 1999 and 2004–
2009 [median (95% CI) IC50: 157.0 (128.0–193.0), 120.5
(105.7–137.3) and 70.0 (10.0-183.0) nM, respectively]
[18,36,37]. Molecular analysis in either laboratory or
field P. falciparum isolates demonstrated the strong link-
age between CQ resistance and pfcrt gene mutations
[20,22,38]. Susceptibility of the parasite to CQ was also
shown in this study to link with pfmrp1 polymorphism, of
which the 191Y mutation resulted in increased susceptibil-
ity of the parasite to CQ. For QN, a decline in parasite
sensitivity to the drug was obviously observed during
1991–1992 and 1994 [mean (95% CI) IC50 576.2 (460.51-
720.99) and 403.9 (330.50-493.54) nM, respectively], but
was improved during 1997–2008 [18,36,37,39]. A total of
16 isolates were identified as QN resistance, 12 and four
isolates collected during 2006–2007 and 2008–2009,
respectively.
Pfmdr1 and pfmrp1 appear to be the key genes in-
volved in resistance of P. falciparum to the commonly
used anti-malarial drugs. The pfmdr1 86Y mutation
leads to increase in susceptibility of the parasite to MQ
compared with wild type genotype (IC50 of 8.1 and 30.4
nM, respectively) as well as the structurally related anti-
malarial QN (IC50 of 86.4 and 236.3 nM). The results
showed low prevalence of 184F allele in parasite isolates
collected during the investigation period. The 184F allele
was reported to be associated with increased IC50 of
MQ. High prevalence of (~86%) of the 184F allele was
reported in western Cambodia where the level of MQ
resistance was significant. On the other hand, theprevalence of 184F allele in eastern Cambodia was low
(~32%), which was also correlated with the reduced level
of MQ resistance in this region [40]. Molecular analysis
in the current study revealed an obvious involvement of
pfmdr1 and pfmrp1 genes with QN-resistant P. falcip-
arum [13,14,21,41]. The pfmdr1 86Y and pfmrp1 1390I
mutations resulted in an improvement of sensitivity of the
parasite to QN compared with the wild type isolates [(86.4
vs 236.3 nM) and (190.2 vs 238.0 nM), respectively]. On the
other hand, the mutation and heterozygous mutation of
pfmdr1 1034C resulted in the decreased susceptibility of
the parasite to QN (median IC50 of 230.5, 256.9 and 190.3
nM for mutated, heterozygous mutated and wild type geno-
types, respectively). Interestingly, the prevalence of pfmrp1
1390 (I) in parasite isolates collected during 2008–2009 was
higher than that collected during 2006–2007.
With regard to the pfatp6 polymorphisms, there were
no mutations found at codons 37, 639 and 769 in sam-
ples collected during 2006–2009. The mutation at codon
898 was found in isolates collected from 2008–2009. Al-
though this residue is silent mutation, this observation
may imply on the influence of anti-malarial drug pres-
sure on the parasite during that period. The finding was
in agreement with that reported by Jambou and colleges
for the isolates in Asia including Thailand [11]. It is
noted however that in vitro cultivation may cause the
poor fitness of the mutant genotypes, which may explain
the observation of almost absence of the mutation in
pfatp6 gene in this study [42].
The current results support the role of pfmdr1 amplifi-
cation in modulating the degree of AS, MQ and QN sus-
ceptibility [43,44] A trend of increasing number of gene
copies and increasing IC50 values of AS, MQ and QN
was clearly observed. Approximately 51% of the isolates
carried pfmdr1 copy number ranging from two to
eight copies. The study conducted during 1995–2007,
the period of which the clinical efficacy of AS-MQ
combination was satisfactory, showed the increase in
pfmdr1copy number from 30% (12/40) in 1996 to 53%
(24/45) in 2006 [45]. Besides the high level of initial
parasitaemia, prolongation of parasite clearance time
and reduced in vitro parasite sensitivity to MQ, treat-
ment failure following AS-MQ combination therapy was
also associated with increased pfmdr1 copy number.
Parasite isolates collected prior to treatment from pa-
tients with recrudescent response were found to carry
higher number of pfmdr1 copies compared to those with
sensitive response (mean copies of 2.7 vs 1.9). In
addition, isolates collected on the day of recrudescence
carried higher number of gene copies than the corre-
sponding day 0 samples (mean copies 3.5 vs 2.6) [35]. In
a previous study, about 70% of isolates collected from
patients with recrudescence response before AS-MQ
treatment was shown to carry more than 1 pfmdr1 copy
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ciated with reduced parasite sensitivity to AS, or resist-
ant to MQ, or both [34]. Although the artemisinin
resistance has not been clearly defined in this study, re-
sults suggest that both the parasite (reduced in vitro sen-
sitivity and increased pfmdr1 copy number) and host
(pharmacokinetic variability) factors might contribute to
artemisinin resistance [9,46].
Conclusions
Based on results of the current observation on in vitro
sensitivity and candidate molecular markers of resist-
ance, it is concluded that high prevalence of MQ resist-
ance still remained during the four years’ observation
period (2006–2009). In addition, sensitivity of the para-
site to AS appeared to be declining. Pfmdr1 gene copy
number is the key molecular marker of resistance of P.
falciparum isolates in this area to AS-MQ combination
therapy.
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